News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Novel EGFR inhibitor shows potential in REZILIENT 3
06 Oct 2026
byAudrey Abella
In the phase III REZILIENT* 3 trial, adding zipalertinib to chemotherapy improves progression-free survival (PFS) in patients with treatment-naïve metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations (ex20ins-mut).
06 Oct 2026







